Linda L Werling
Overview
Explore the profile of Linda L Werling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Werling L, Collins Reed S, Wade D, Izenwasser S
Int J Dev Neurosci
. 2009 Jan;
27(3):263-9.
PMID: 19167478
A significant number of youths use cigarettes, and more than half of the youths who smoke daily also use illicit drugs. The focus of these studies is on how exposure...
2.
Werling L, Lauterbach E, Calef U
Neurologist
. 2007 Sep;
13(5):272-93.
PMID: 17848867
Background: Dextromethorphan (DM) is a widely-used antitussive. DM's complex central nervous system (CNS) pharmacology became of interest when it was discovered to be neuroprotective due to its low-affinity, uncompetitive N-methyl-D-aspartate...
3.
Werling L, Keller A, Frank J, Nuwayhid S
Exp Neurol
. 2007 Aug;
207(2):248-57.
PMID: 17689532
We compared the binding profiles of medications potentially useful in the treatment of involuntary emotional expression disorder at twenty-six binding sites in rat brain tissue membranes. Sites were chosen based...
4.
Nuwayhid S, Werling L
Eur J Pharmacol
. 2006 Feb;
535(1-3):98-103.
PMID: 16480713
Studies from our laboratory have shown that agonists at sigma1 and sigma2 receptors inhibit N-methyl-D-aspartate (NMDA)-stimulated dopamine release from motor and limbic areas of rat brain. In the current study,...
5.
Awtry T, Frank J, Werling L
Synapse
. 2006 Feb;
59(6):342-9.
PMID: 16463401
We investigated the effect of in vitro exposure to nicotinic acetylcholine receptors (nAChRs), agonists, antagonists, and protein kinase A (PKA) modulators on the activity of the serotonin transporter (SERT) in...
6.
Hong W, Nuwayhid S, Werling L
Synapse
. 2004 Sep;
54(2):102-10.
PMID: 15352135
In this study we investigated the effects of sigma receptor ligands and neurosteroids on bradykinin-induced intracellular calcium concentration ([Ca2+]i) changes in SH-SY5Y neuroblastoma cells. [Ca2+]i levels in cells loaded with...
7.
Drew A, Werling L
Schizophr Res
. 2003 Nov;
65(1):47-55.
PMID: 14623374
Low levels of dopaminergic activity in prefrontal cortex are thought to contribute to negative symptoms of schizophrenia. Negative symptoms are associated with the prefrontocortical area of the brain. Schizophrenic patients...
8.
Awtry T, Werling L
Synapse
. 2003 Sep;
50(3):206-11.
PMID: 14515338
We sought to investigate the effect of nicotine exposure (chronic and acute) on serotonin transporter (SERT) activity in two regions of the brain important for behavioral effects of nicotine. We...
9.
Nuwayhid S, Werling L
J Pharmacol Exp Ther
. 2003 May;
306(3):934-40.
PMID: 12750428
Steroids have been proposed as endogenous ligands at sigma receptors. In the current study, we examined the ability of steroids to regulate N-methyl-d-aspartate (NMDA)-stimulated [3H]dopamine release from slices of rat...
10.
Nuwayhid S, Werling L
J Pharmacol Exp Ther
. 2002 Dec;
304(1):364-9.
PMID: 12490613
We have previously shown that sigma1 receptor agonists inhibit N-methyl-D-aspartate (NMDA)-stimulated [3H]dopamine from slices of rat striatum in a concentration-related manner and that the inhibition is reversed by sigma1 receptor-selective...